AR048532A1 - Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininas - Google Patents
Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininasInfo
- Publication number
- AR048532A1 AR048532A1 ARP050101376A ARP050101376A AR048532A1 AR 048532 A1 AR048532 A1 AR 048532A1 AR P050101376 A ARP050101376 A AR P050101376A AR P050101376 A ARP050101376 A AR P050101376A AR 048532 A1 AR048532 A1 AR 048532A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- radical
- group
- amino
- integer equal
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- -1 cyano, hydroxy, formyl Chemical group 0.000 abstract 12
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 abstract 4
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001544 thienyl group Chemical group 0.000 abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- 125000000815 N-oxide group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 abstract 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000002971 oxazolyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005883 dithianyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente comprende sus sales de adicion de base o ácido farmacéuticamente aceptables; sus formas estereoquímicamente isomeras; su forma de N-oxido; y sus profármacos. Reivindicacion 1: Un compuesto de acuerdo con la formula general (1), sus sales de adicion de ácido o base farmacéuticamente aceptables, sus formas estereoquímicamente isomeras, su forma N-oxido y sus profármacos, en donde: n es un entero igual a 0, 1 o 2; m es un entero igual a 1 o 2, siempre que si m es 2 entonces n es 1; cada R1, de manera independiente entre sí, se selecciona del grupo de Ar1, Ar1-alquilo y di(Ar1)-alquilo; R4 se selecciona del grupo de hidrogeno, hidroxi y alquiloxi; Z es un radical bivalente -(CH2)r-, en donde r es un entero igual a 1, 2, 3, 4 o 5, y en donde un radical -CH2- está opcionalmente reemplazado por un radical >C(=O); o R4 y Z se toman juntos para formar un radical trivalente =CH-(CH2)r-1-, en donde r es un entero igual a 2, 3, 4, o 5, y en donde un radical -CH2- está opcionalmente reemplazado por un radical >C=O; p es un entero igual a 1 o 2; Q es O o NR3; X es un enlace covalente o un radical bivalente de formula -O-, -S-, o -NR3-; cada R3, de manera independientemente entre sí, es hidrogeno o alquilo; R2 es alquilo, Ar2, Ar2-alquilo, Het1 o Het1-alquilo; q es un entero igual a 0 o 1; j es un entero igual a 0, 1 o 2; k es un entero igual a 0, 1 o 2; Y es un enlace covalente o un radical bivalente de formula >C(=O) o -SO2-; cada Alk representa, de manera independiente entre sí, un enlace covalente; un radical hidrocarburo bivalente recto o ramificado, saturado o insaturado C1-6; o un radical hidrocarburo cíclico saturado o insaturado C3-6; cada radical está opcionalmente sustituido en uno o más átomos de carbono con uno o más radicales alquilo, fenilo, halo, ciano, hidroxi, formilo y amino; L se selecciona del grupo de hidrogeno, alquilo, alquiloxi, Ar3-oxi, alquiloxicarbonilo, mono- y di(alquil)amino, mono- y di(Ar3)amino, mono- y di(alquiloxicarbonil)amino, Ar3, Ar3-carbonilo, Het2, Het2-carbonilo; Ar1 es fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes en donde cada uno, de manera independiente entre sí, se selecciona del grupo de halo, alquilo, ciano, aminocarbonilo y alquiloxi; Ar2 es naftalenilo o fenilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes en donde cada sustituyente, de manera independiente entre sí, seleccionado del grupo de halo, nitro, amino, mono- y di(alquil)amino, ciano, alquilo, hidroxi, alquiloxi, carboxilo, alquiloxicarbonilo, aminocarbonilo, y mono- y di(alquil)aminocarbonilo; Ar3 es naftalenilo o fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes en donde cada sustituyente independiente entre sí, se selecciona del grupo de alquiloxi, alquilo, halo, hidroxi, piridinilo, morfolinilo, pirrolidinilo, imidazo[1,2-alfa]piridinilo, morfolinilcarbonilo, pirrolidinilcarbonilo, amino y ciano; Het1 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, y piridazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, bencimidazolilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzofuranilo y benzotienilo; cada radical heterocíclico puede estar opcionalmente sustituido en cualquiera átomo con uno o más radicales seleccionados del grupo de halo y alquilo; Het2 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolidinilo, dioxolilo, imidazolidinilo, pirrazolidinilo, piperidinilo, morfolinilo, ditianilo, tiomorfolinilo, piperazinilo, imidazolidinilo, tetrahidrofuranilo, 2H-pirrolilo, pirrolinilo, imidazolinilo, pirrazolinilo, pirrolilo, imidazolilo, pirazolilo, triazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, triazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de benzopiperidinilo, quinolinilo, quinoxalinilo, indolilo, isoindolilo, cromenilo, bencimidazolilo, imidazo[1,2-alfa]piridinilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzofuranilo, y benzotienilo; cada radical heterocíclico puede estar opcionalmente sustituido en cualquier átomo con uno o más radicales seleccionados del grupo de Ar1, Ar1alquilo, halo, hidroxi, alquilo, piperidinilo, pirrolilo, tienilo, oxo, alquiloxi, alquiloxialquilo y alquiloxicarbonilo; Alquilo es un radical hidrocarburo saturado, recto o ramificado C1-6; o un radical hidrocarburo saturado cíclico C3-6; opcionalmente sustituido en uno o más átomos de carbono con uno o más radicales seleccionados del grupo de fenilo, halo, ciano, oxo, hidroxi, formilo y amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101467 | 2004-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048532A1 true AR048532A1 (es) | 2006-05-03 |
Family
ID=34928945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101376A AR048532A1 (es) | 2004-04-08 | 2005-04-07 | Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070213346A1 (es) |
| EP (1) | EP1737838B1 (es) |
| JP (1) | JP2007532516A (es) |
| KR (1) | KR20070007347A (es) |
| CN (1) | CN1938291B (es) |
| AR (1) | AR048532A1 (es) |
| AT (1) | ATE396185T1 (es) |
| AU (1) | AU2005231986B2 (es) |
| BR (1) | BRPI0509720A (es) |
| CA (1) | CA2561967A1 (es) |
| DE (1) | DE602005007002D1 (es) |
| EA (1) | EA010312B1 (es) |
| ES (1) | ES2307169T3 (es) |
| IL (1) | IL178461A0 (es) |
| JO (1) | JO2525B1 (es) |
| MX (1) | MXPA06011683A (es) |
| MY (1) | MY142773A (es) |
| NO (1) | NO20065022L (es) |
| NZ (1) | NZ550098A (es) |
| PA (1) | PA8628901A1 (es) |
| TW (1) | TWI358298B (es) |
| WO (1) | WO2005097774A1 (es) |
| ZA (1) | ZA200608356B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20061012A1 (es) * | 2005-02-23 | 2006-10-03 | Schering Corp | Derivados piperidinil piperazina como inhibidores de receptores quiomicina |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| CN102369186B (zh) | 2009-04-02 | 2014-07-09 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物 |
| WO2010114181A1 (en) | 2009-04-02 | 2010-10-07 | Shionogi & Co., Ltd. | Acrylamide compounds and the use thereof |
| CA2779073C (en) * | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| JP6231691B2 (ja) * | 2013-09-12 | 2017-11-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドール−カルボキサミド誘導体 |
| KR102704783B1 (ko) | 2015-05-18 | 2024-09-10 | 칸디 테라퓨틱스 리미티드 | 성-호르몬 의존성 질환의 치료를 위한 이중 nk-1/nk-3 수용체 길항제 |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| EP3983368B1 (en) | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| JP7355858B2 (ja) * | 2019-06-12 | 2023-10-03 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | 水性側流からカルボン酸を単離するための方法 |
| ES2963382T3 (es) | 2019-06-12 | 2024-03-26 | Nouryon Chemicals Int Bv | Proceso para la producción de peróxidos de diacilo |
| US12209065B2 (en) | 2019-06-12 | 2025-01-28 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| US12215074B2 (en) | 2019-06-12 | 2025-02-04 | Nouryon Chemicals International B.V. | Process for the production of peroxyesters |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW382017B (en) * | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| AU2003298369B2 (en) * | 2002-12-23 | 2009-08-27 | Janssen Pharmaceutica N.V. | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
-
2005
- 2005-03-22 JO JO200534A patent/JO2525B1/en active
- 2005-04-04 JP JP2007506775A patent/JP2007532516A/ja not_active Ceased
- 2005-04-04 CA CA002561967A patent/CA2561967A1/en not_active Abandoned
- 2005-04-04 AT AT05729797T patent/ATE396185T1/de active
- 2005-04-04 CN CN2005800108231A patent/CN1938291B/zh not_active Expired - Fee Related
- 2005-04-04 KR KR1020067021935A patent/KR20070007347A/ko not_active Ceased
- 2005-04-04 MX MXPA06011683A patent/MXPA06011683A/es active IP Right Grant
- 2005-04-04 EP EP05729797A patent/EP1737838B1/en not_active Expired - Lifetime
- 2005-04-04 BR BRPI0509720-7A patent/BRPI0509720A/pt not_active IP Right Cessation
- 2005-04-04 EA EA200601880A patent/EA010312B1/ru not_active IP Right Cessation
- 2005-04-04 NZ NZ550098A patent/NZ550098A/en unknown
- 2005-04-04 DE DE602005007002T patent/DE602005007002D1/de not_active Expired - Lifetime
- 2005-04-04 AU AU2005231986A patent/AU2005231986B2/en not_active Ceased
- 2005-04-04 US US11/547,868 patent/US20070213346A1/en not_active Abandoned
- 2005-04-04 WO PCT/EP2005/051509 patent/WO2005097774A1/en not_active Ceased
- 2005-04-04 ES ES05729797T patent/ES2307169T3/es not_active Expired - Lifetime
- 2005-04-05 PA PA20058628901A patent/PA8628901A1/es unknown
- 2005-04-06 MY MYPI20051549A patent/MY142773A/en unknown
- 2005-04-07 TW TW094110941A patent/TWI358298B/zh not_active IP Right Cessation
- 2005-04-07 AR ARP050101376A patent/AR048532A1/es not_active Application Discontinuation
-
2006
- 2006-10-05 IL IL178461A patent/IL178461A0/en unknown
- 2006-10-06 ZA ZA200608356A patent/ZA200608356B/en unknown
- 2006-11-03 NO NO20065022A patent/NO20065022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PA8628901A1 (es) | 2006-09-08 |
| TWI358298B (en) | 2012-02-21 |
| US20070213346A1 (en) | 2007-09-13 |
| WO2005097774A1 (en) | 2005-10-20 |
| JO2525B1 (en) | 2010-03-17 |
| EA010312B1 (ru) | 2008-08-29 |
| BRPI0509720A (pt) | 2007-09-25 |
| EA200601880A1 (ru) | 2007-02-27 |
| MXPA06011683A (es) | 2006-12-14 |
| KR20070007347A (ko) | 2007-01-15 |
| CA2561967A1 (en) | 2005-10-20 |
| EP1737838B1 (en) | 2008-05-21 |
| TW200603797A (en) | 2006-02-01 |
| AU2005231986A1 (en) | 2005-10-20 |
| MY142773A (en) | 2010-12-31 |
| EP1737838A1 (en) | 2007-01-03 |
| NZ550098A (en) | 2009-10-30 |
| ATE396185T1 (de) | 2008-06-15 |
| AU2005231986B2 (en) | 2011-02-24 |
| JP2007532516A (ja) | 2007-11-15 |
| ZA200608356B (en) | 2008-07-30 |
| IL178461A0 (en) | 2007-02-11 |
| DE602005007002D1 (de) | 2008-07-03 |
| CN1938291A (zh) | 2007-03-28 |
| ES2307169T3 (es) | 2008-11-16 |
| CN1938291B (zh) | 2011-11-16 |
| NO20065022L (no) | 2006-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041545A1 (es) | Derivados sustituidos de 1,4-di-piperidin-4 il-piperazina y su uso como antagonistas de neuroquininas | |
| AR048532A1 (es) | Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininas | |
| AR048522A1 (es) | Derivados sustituidos de diaza-espiro-(5.5)-undecano y su uso como antagonistas de neuroquininas | |
| AR048521A1 (es) | Derivados sustituidos de diaza-espiro-(4.5)-decano y su uso como antagonistas de neuroquininas | |
| AR035991A1 (es) | Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio | |
| AR087051A2 (es) | Una composicion inhibidora del virus de la hepatitis c y uso | |
| AR005277A1 (es) | Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| AR067528A1 (es) | Eteres heterociclicos sustituidos y su uso en trastornos del snc | |
| AR040475A1 (es) | Espiropiperidinas o espiropirrolidinas triciclicas | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| CR20190465A (es) | COMPOSICIONES PARA EL CONTROL DE PLAGAS QUE INCLUYE UN DERIVADO DE IMINOPIRIDINA NOVEDOSO (Divisional 2014-0450) | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| BR112014006840A2 (pt) | derivados de pirrolopirimidina e purina | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| MX346367B (es) | Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo. | |
| AR055635A1 (es) | Uso de sulfonanilidas como herbicidas | |
| UY31950A (es) | Inhibidores de ciclopropil-polimerasa | |
| UA116794C2 (uk) | Моноциклічна піридинова похідна | |
| BR112012021198A2 (pt) | composto de pirazolopirimidina e seu uso como inibidores de pde10 | |
| TW201129540A (en) | Method for producing cycloalkane dicarboxylic acid monoester | |
| AR042651A1 (es) | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |